Prescribing information for LUTATHERA® (lutetium (177Lu) oxodotreotide) (external link)
Prescribing information for Pluvicto®▼ (lutetium (177Lu) vipivotide tetraxetan) (external link)
Prescribing information for Locametz®▼ (gozetotide) (external link)
Prescribing information for SomaKit TOC® (edotreotide) (external link)
This page includes promotional meetings and events organised and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned on this page and/or subsequent event pages.
Radioligand therapy (RLT)
LUTATHERA® (lutetium [177Lu] oxodotreotide)
PLUVICTO®▼ (lutetium [177Lu] vipivotide tetraxetan)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
